Cohen Milstein Sellers & Toll PLLC Announces the Investigation of Enzymotec Ltd.

WASHINGTON, Sept. 30, 2014 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether Enzymotec Ltd. ("Enzymotec" or the "Company") and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 or violated the Securities Act of 1933.

A class action lawsuit was filed in the U.S. District Court for the District of New Jersey by another law firm on behalf of purchasers of the common stock of Enzymotec Ltd. (Nasdaq:ENZY) between September 27, 2013, and August 4, 2014, inclusive (the "Class Period"), including those who purchased shares pursuant or traceable to the Company's September 27, 2013, initial public offering ("IPO").

The complaint alleges that Enzymotec and certain of its officers and directors ("Defendants") misrepresented and/or failed to disclose that: (1) Enzymotec was facing significant compliance issues in the Chinese market, increased competition and operational problems; (2) the Company's Chinese baby formula business was in jeopardy and subject to increased volatility and decreased revenues as it was subject to material and readily identifiable compliance regulations from the Chinese government; (3) the Company's joint venture with AarhusKarlshamn AB ("AAK") was in jeopardy, exposing the Company to liability and decreased revenues; and (4) as a result of the foregoing, the Defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading or lacked a reasonable basis.

The Class Period ends with the Company's release of second quarter results that were far worse than its previous guidance and analysts' expectations, including an almost 40% year-over-year decline in revenues and EPS of $0.02 versus analysts' estimates of $0.10. According to Defendants, the two primary factors impacting the second quarter performance were "recent regulatory changes in the Chinese infant formula market" and weakness in the Omega-3 industry, especially in the U.S. and Australia. Enzymotec also drastically reduced its guidance for FY 2014. The price of Enzymotec shares fell from $14.98 to $9.11 on August 5, 2014.

Cohen Milstein encourages all investors who purchased Enzymotec common stock between September 27, 2013, and August 4, 2014, inclusive, including those who purchased shares pursuant or traceable to the Company's September 27, 2013, IPO, or former employees with information concerning this matter to contact the firm.

If you are an Enzymotec shareholder and would like to discuss your right to recover for your economic loss, you may, without any cost or obligation, call Cohen Milstein's Managing Partner, Steven J. Toll at (888) 240-0775 or (202) 408-4600, or email him at stoll@cohenmilstein.com. If you wish to serve as lead plaintiff, you must move the Court no later than November 4, 2014, to request appointment. Any member of the proposed class may retain Cohen Milstein or other attorneys to serve as your counsel in this action, or you may do nothing and remain an absent class member.

Cohen Milstein has significant experience in prosecuting investor class actions and actions involving securities fraud, and is active in major litigation pending in federal and state courts throughout the nation. Cohen Milstein has taken a lead role in numerous important cases on behalf of defrauded investors, and has been responsible for a number of outstanding recoveries which, in the aggregate, total over two billion dollars. Prior results do not guarantee a similar outcome. For more information visit www.cohenmilstein.com.

If you have any questions about this notice or the action, or with regard to your rights, please contact either of the following:

Attorney Advertising